Article Text

Review: weight-reducing agents improve glycaemic control and reduce progression to diabetesCommentary

Statistics from

S Czernichow

Dr S Czernichow, Unite de Recherche en Nutrition Humaine, Bobigny, France;


How do weight-reducing agents affect glycaemic parameters and risk of type 2 diabetes in predisposed individuals?


Included studies were randomised, double-blind, placebo controlled trials (RCTs) that evaluated the effects of weight-reducing agents (eg, orlistat, sibutramine, and rimonabant) on fasting glucose or glycated haemoglobin (HbA1c) concentrations and had a duration of ⩾1 year. Studies of mixed populations were excluded. Outcomes included weight loss, fasting glucose and HbA1c concentrations, and diabetes.


Medline was searched from …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.